GlassScriptPhysician profile
Yanis Boumber
NPI 1780870428
$101,123.28
in general payments reported to CMS, 2019-2025
24 companies · $321 in 2025
The $321 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,229 · 2020: $555 · 2021: $29K · 2022: $40K · 2023: $29K · 2024: $32.46 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $1,409 · Travel and Lodging: $1,202 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,523.23 |
| Food and Beverage | $1,408.57 |
| Travel and Lodging | $1,201.99 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $42,321.41 | 2021-2023 | Libtayo |
| Genzyme Corporation | $25,259.95 | 2021-2023 | |
| Amgen INC. | $24,475.82 | 2021-2025 | Imdelltra (Amg757), Lumakras |
| Astrazeneca Pharmaceuticals LP | $3,800.41 | 2019-2025 | Imfinzi |
| Jazz Pharmaceuticals INC. | $1,958.88 | 2021-2022 | |
| G1 Therapeutics, INC. | $1,500.00 | 2021 | |
| Lilly USA, LLC | $700.00 | 2021 | |
| Novocure INC. | $553.58 | 2021-2025 | Optune Lua (Novottf-200t) |
| Merck Sharp & Dohme LLC | $122.12 | 2022-2025 | Keytruda |
| Coherus Oncology, INC. | $121.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $79.35 | 2022 | |
| Pharmacosmos Therapeutics INC. | $43.27 | 2023-2025 | Monoferric |
| Genentech, INC. | $34.96 | 2025 | Tecentriq |
| Eisai INC. | $34.17 | 2025 | |
| Janssen Biotech, INC. | $24.29 | 2025 | Rybrevant |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $22.36 | 2022 | |
| Janssen Scientific Affairs, LLC | $20.73 | 2025 | Rybrevant |
| Abbvie INC. | $17.86 | 2023 | Venclexta |
| Tempus Ai, INC | $17.34 | 2024 | |
| Genentech USA, INC. | $15.34 | 2023 | Rozlytrek, Tecentriq, Alecensa |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yanis Boumber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.